168 related articles for article (PubMed ID: 9292531)
1. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia.
Jahns-Streubel G; Reuter C; Auf der Landwehr U; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
Blood; 1997 Sep; 90(5):1968-76. PubMed ID: 9292531
[TBL] [Abstract][Full Text] [Related]
2. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
Jahns-Streubel G; Reuter C; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1995 Nov; 9(11):1857-63. PubMed ID: 7475275
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts.
Reuter C; Schleyer E; Rolf C; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1997 Apr; 11(4):561-71. PubMed ID: 9096697
[TBL] [Abstract][Full Text] [Related]
4. The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
Braess J; Voss S; Jahns-Streubel G; Schoch C; Haferlach T; Kern W; Keye S; Schleyer E; Hiddemann W
Br J Haematol; 2000 Jul; 110(1):170-9. PubMed ID: 10930995
[TBL] [Abstract][Full Text] [Related]
5. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor.
Reuter C; Auf der Landwehr U; Schleyer E; Zühlsdorf M; Ameling C; Rolf C; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1994 Feb; 8(2):217-25. PubMed ID: 8309245
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.
Jahns-Streubel G; Braess J; Schoch C; Fonatsch C; Haase D; Binder C; Wörmann B; Büchner T; Hiddemann W
Leukemia; 2001 Mar; 15(3):377-84. PubMed ID: 11237060
[TBL] [Abstract][Full Text] [Related]
7. No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.
Hast R; Hellström-Lindberg E; Ohm L; Björkholm M; Celsing F; Dahl IM; Dybedal I; Gahrton G; Lindberg G; Lerner R; Linder O; Löfvenberg E; Nilsson-Ehle H; Paul C; Samuelsson J; Tangen JM; Tidefelt U; Turesson I; Wahlin A; Wallvik J; Winquist I; Oberg G; Bernell P
Leukemia; 2003 Sep; 17(9):1827-33. PubMed ID: 12970783
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
Wörmann B; Hiddemann W; Frisch J; Zühlsdorf M; Rottmann R; Boeckmann A; Reuter C; Freire EA; Innig G; Schulz G
Behring Inst Mitt; 1991 Dec; (90):28-38. PubMed ID: 1801688
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse.
Büchner T; Hiddemann W; Koenigsmann M; Zühlsdorf M; Wörmann B; Boeckmann A; Freire EA; Innig G; Maschmeyer G; Ludwig WD
Blood; 1991 Sep; 78(5):1190-7. PubMed ID: 1878586
[TBL] [Abstract][Full Text] [Related]
11. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
Hiddemann W; Wörmann B; Reuter C; Schleyer E; Zühlsdorf M; Böckmann A; Büchner T
Semin Oncol; 1994 Dec; 21(6 Suppl 16):33-8. PubMed ID: 7528449
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia.
Bettelheim P; Valent P; Andreeff M; Tafuri A; Haimi J; Gorischek C; Muhm M; Sillaber C; Haas O; Vieder L
Blood; 1991 Feb; 77(4):700-11. PubMed ID: 1993213
[TBL] [Abstract][Full Text] [Related]
13. Changing response of clonogenic myeloid leukemia blasts to granulocyte-macrophage colony-stimulating factor (GM-CSF) during anti-leukemic therapy--a case report on the basis of a clinical phase II trial.
Hiddemann W; Zühlsdorf M; Wörmann B; Koenigsmann M; Büchner T
Leuk Res; 1990; 14(4):347-52. PubMed ID: 2185381
[TBL] [Abstract][Full Text] [Related]
14. Fatal spleen rupture during induction chemotherapy with rh GM-CSF priming for acute monocytic leukemia. Clinical case report and in vitro studies.
Zimmer BM; Berdel WE; Ludwig WD; Notter M; Reufi B; Thiel E
Leuk Res; 1993 Mar; 17(3):277-83. PubMed ID: 8450676
[TBL] [Abstract][Full Text] [Related]
15. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.
Estey E; Thall PF; Kantarjian H; O'Brien S; Koller CA; Beran M; Gutterman J; Deisseroth A; Keating M
Blood; 1992 May; 79(9):2246-55. PubMed ID: 1571541
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
Hiddemann W; Kiehl M; Zühlsdorf M; Busemann C; Schleyer E; Wörmann B; Büchner T
Semin Oncol; 1992 Apr; 19(2 Suppl 4):31-7. PubMed ID: 1553573
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
Zittoun R; Suciu S; Mandelli F; de Witte T; Thaler J; Stryckmans P; Hayat M; Peetermans M; Cadiou M; Solbu G; Petti MC; Willemze R
J Clin Oncol; 1996 Jul; 14(7):2150-9. PubMed ID: 8683249
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study.
Bernell P; Kimby E; Hast R
Leukemia; 1994 Oct; 8(10):1631-9. PubMed ID: 7934158
[TBL] [Abstract][Full Text] [Related]
19. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group.
Löwenberg B; Suciu S; Archimbaud E; Ossenkoppele G; Verhoef GE; Vellenga E; Wijermans P; Berneman Z; Dekker AW; Stryckmans P; Schouten H; Jehn U; Muus P; Sonneveld P; Dardenne M; Zittoun R
Blood; 1997 Oct; 90(8):2952-61. PubMed ID: 9376575
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia.
Frenette PS; Desforges JF; Schenkein DP; Rabson A; Slapack CA; Miller KB
Am J Hematol; 1995 May; 49(1):48-55. PubMed ID: 7741138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
